ldlr elisa kit Search Results


94
R&D Systems human ldl r immunoassay
Human Ldl R Immunoassay, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ldlr+elisa+kit/Human+LDLR+Quantikine+ELISA+Kit/us12552807-2237-29-33
Average 94 stars, based on 1 article reviews
human ldl r immunoassay - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

94
R&D Systems mouse ldlr elisa kit
The pharmacophore model of the <t>LDLR-binding</t> domain in PCSK9 was established using MOE. Pharmacophore features include: F1, an aromatic feature; F2 and F4, hydrogen-bond acceptor features; F3, a hydrogen-bond donor feature.
Mouse Ldlr Elisa Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ldlr+elisa+kit/Mouse+LDLR+Quantikine+ELISA+Kit/pmc12829418-177-12-16
Average 94 stars, based on 1 article reviews
mouse ldlr elisa kit - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

94
R&D Systems elisa kit
Translation <t>of</t> <t>LDLR</t> protein is enhanced by targeting the predicted structure using an ASO. ( A ) The potential effect of an ASO on the predicted structure is depicted. ( B ) <t>ELISA</t> analyses for LDLR protein levels in HEK293 cells transfected for 15 h with XL824, which targets the 5′ side of the predicted stem. ( C ) qRT-PCR quantification of LDLR mRNA in cells treated with XL824. ( D ) ELISA analyses for LDLR protein in HEK293 cells transfected for 15 h with ASO814923, targeting the 3′ side of the potential stem or an ASO XL506 targeting a potential uORF. ASO concentration 0 indicates mock transfection. ( E ) Western analyses for LDLR protein in HEK293 cells treated with 30 nM ASO814923 for 10 h. Levels were normalized to those of GAPDH. ( F ) qRT-PCR quantification of LDLR mRNA levels in HEK293 cells treated with the ASO. ( G ) Autoradiography of 35 S-methionine-labeled nascent LDLR protein isolated by immunoprecipitation from cells treated with ASO814923 (+) or mock-treated (–) for 7 h. An aliquot of cell lysate used for immunoprecipitation was analyzed by SDS-PAGE, and labeled nascent proteins were visualized by autoradiography (right panel). The level of nascent LDLR protein was normalized to signal from band marked by an arrow, and relative levels are given below the lanes. ( H ) qRT-PCR quantification of LDLR mRNA co-immunoprecipitated using an anti-eIF4A antibody or control IgG from mock transfected HEK293 cells (UTC) or cells treated with the ASO814923 for 10 h. 7SL RNA and RNASEH1 mRNA were quantified as controls. ( I ) LDL uptake in HEK293 cells treated with 30 nM ASO814923 or 30 nM control ASO812662 for 15 h. ( J ) qRT-PCR for LDLR mRNA levels in HEK293 cells treated with siRNA targeting luc or LDLR for 4 h, followed by treatment with or without ASO814923 (40 nM) for an additional 10 h. ( K ) ELISA analyses for LDLR protein levels in HEK293 cells treated with siRNAs, followed by treatment with ASO814923. ( L ) LDL uptake in HEK293 cells treated with siRNAs for 4 h, followed by treatment of the ASO for 10 h, and LDL uptake analysis. The error bars are standard deviations from three experiments. P -values were calculated based on unpaired t-test. NS, not significant. ** P < 0.01; *** P < 0.001 and **** P < 0.0001.
Elisa Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ldlr+elisa+kit/Human+LDLR+Quantikine+ELISA+Kit/pmc05766168-64-9-12
Average 94 stars, based on 1 article reviews
elisa kit - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

93
Cusabio human low density lipoprotein receptor
Translation <t>of</t> <t>LDLR</t> protein is enhanced by targeting the predicted structure using an ASO. ( A ) The potential effect of an ASO on the predicted structure is depicted. ( B ) <t>ELISA</t> analyses for LDLR protein levels in HEK293 cells transfected for 15 h with XL824, which targets the 5′ side of the predicted stem. ( C ) qRT-PCR quantification of LDLR mRNA in cells treated with XL824. ( D ) ELISA analyses for LDLR protein in HEK293 cells transfected for 15 h with ASO814923, targeting the 3′ side of the potential stem or an ASO XL506 targeting a potential uORF. ASO concentration 0 indicates mock transfection. ( E ) Western analyses for LDLR protein in HEK293 cells treated with 30 nM ASO814923 for 10 h. Levels were normalized to those of GAPDH. ( F ) qRT-PCR quantification of LDLR mRNA levels in HEK293 cells treated with the ASO. ( G ) Autoradiography of 35 S-methionine-labeled nascent LDLR protein isolated by immunoprecipitation from cells treated with ASO814923 (+) or mock-treated (–) for 7 h. An aliquot of cell lysate used for immunoprecipitation was analyzed by SDS-PAGE, and labeled nascent proteins were visualized by autoradiography (right panel). The level of nascent LDLR protein was normalized to signal from band marked by an arrow, and relative levels are given below the lanes. ( H ) qRT-PCR quantification of LDLR mRNA co-immunoprecipitated using an anti-eIF4A antibody or control IgG from mock transfected HEK293 cells (UTC) or cells treated with the ASO814923 for 10 h. 7SL RNA and RNASEH1 mRNA were quantified as controls. ( I ) LDL uptake in HEK293 cells treated with 30 nM ASO814923 or 30 nM control ASO812662 for 15 h. ( J ) qRT-PCR for LDLR mRNA levels in HEK293 cells treated with siRNA targeting luc or LDLR for 4 h, followed by treatment with or without ASO814923 (40 nM) for an additional 10 h. ( K ) ELISA analyses for LDLR protein levels in HEK293 cells treated with siRNAs, followed by treatment with ASO814923. ( L ) LDL uptake in HEK293 cells treated with siRNAs for 4 h, followed by treatment of the ASO for 10 h, and LDL uptake analysis. The error bars are standard deviations from three experiments. P -values were calculated based on unpaired t-test. NS, not significant. ** P < 0.01; *** P < 0.001 and **** P < 0.0001.
Human Low Density Lipoprotein Receptor, supplied by Cusabio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ldlr+elisa+kit/Human+low+density+lipoprotein+receptor%2CLDLR+ELISA+Kit/pmc12786223-260-6-13
Average 93 stars, based on 1 article reviews
human low density lipoprotein receptor - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

94
R&D Systems quantikine elisa kit
PCSK9 vaccine (V2 vaccine) or control (Saline) was injected at different doses (Low; 5 μg and High; 50 μg peptides per mouse) three times in biweekly intervals (0, 2, and 4 weeks). (A) Anti-PCSK9 antibody titers (OD50%) were evaluated at pre-immunization (pre) and post-immunization time points (2, 4, 6, 8, 12, 16, 20, and 24 weeks). Data are presented as the average of each groups; error bars indicate the SEM. **P<0.01 and ****P<0.0001 show significant changes between low dose group and saline group. ††††P<0.0001 shows significant changes between high dose group and saline group. (B) PCSK9 levels in plasma samples from pre-immunized (pre) and post-immunized (6 weeks) mice. Bars represent mean levels of detected mouse PCSK9 levels in plasma samples, and error bars represent ± SEM. Significance values relative to saline group (*P<0.05, ***P<0.001) were obtained using two-way ANOVA with subsequent Tukey's multiple comparisons tests. (C) Cell-surface LDLR levels in liver hepatocytes were measured in immunized mice at 6 weeks post-immunization via <t>ELISA.</t> The results are presented as a fold-increase relative to saline-treated groups. Significance values relative to saline (****P<0.0001) were obtained with one-way ANOVA with subsequent Tukey’s tests for multiple comparisons. All data in this Figure are expressed as the means ± SEM.
Quantikine Elisa Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ldlr+elisa+kit/Mouse+LDLR+Quantikine+ELISA+Kit/pmc05811007-46-11-15
Average 94 stars, based on 1 article reviews
quantikine elisa kit - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

90
Absolute Biotech Inc ldlr elisa kit
PCSK9 vaccine (V2 vaccine) or control (Saline) was injected at different doses (Low; 5 μg and High; 50 μg peptides per mouse) three times in biweekly intervals (0, 2, and 4 weeks). (A) Anti-PCSK9 antibody titers (OD50%) were evaluated at pre-immunization (pre) and post-immunization time points (2, 4, 6, 8, 12, 16, 20, and 24 weeks). Data are presented as the average of each groups; error bars indicate the SEM. **P<0.01 and ****P<0.0001 show significant changes between low dose group and saline group. ††††P<0.0001 shows significant changes between high dose group and saline group. (B) PCSK9 levels in plasma samples from pre-immunized (pre) and post-immunized (6 weeks) mice. Bars represent mean levels of detected mouse PCSK9 levels in plasma samples, and error bars represent ± SEM. Significance values relative to saline group (*P<0.05, ***P<0.001) were obtained using two-way ANOVA with subsequent Tukey's multiple comparisons tests. (C) Cell-surface LDLR levels in liver hepatocytes were measured in immunized mice at 6 weeks post-immunization via <t>ELISA.</t> The results are presented as a fold-increase relative to saline-treated groups. Significance values relative to saline (****P<0.0001) were obtained with one-way ANOVA with subsequent Tukey’s tests for multiple comparisons. All data in this Figure are expressed as the means ± SEM.
Ldlr Elisa Kit, supplied by Absolute Biotech Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ldlr+elisa+kit/ldlr+elisa+kit/pmc10839302-172-30-33
Average 90 stars, based on 1 article reviews
ldlr elisa kit - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Cell Biolabs Inc sandwich elisa kit detection ldlr
(A) Predicted annealing of human miR-27a to two sites on the <t>LDLR</t> 3′UTR. HepG2 cells were transfected with different concentrations of either LNA anti-miR-27a or LNA NC. (B) Cells were transfected with either 30 nM miR-27a, 30 nM NC mimic, 50 nM LNA anti-miR-27a or 50 nM LNA NC. The level of LDLR mRNA was quantified by TaqMan qPCR and the LDLR protein by <t>ELISA.</t> (C and D) Cells were co-transfected with 1 μg of reporter constructs pLDLR-3′UTR, pmiR-27a or mutated pmiR-27aM in the presence or absence of either 50 nM LNA anti-miR-27a, 50 nM LNA NC, 30 nM miR-27a or 30 nM NC mimic. (E) LDLR activity was assessed in HepG2 cells transfected with either 30 nM miR-27a or NC mimics and incubated overnight with LDL conjugated to DyLight™ 549, a fluorescent probe for detection of LDL uptake. The degree of LDL uptake was examined in an Evos Digital Inverted Fluorescence Microscope (AMG, Fisher Scientific) with filters for excitation at 540 nm and emission at 570 nm. (F) The intensity of fluorescence was quantified at 540/570 nm excitation/emission using a Synergy MX plate reader (Biotek). Data are mean of three independent experiments ± S.D. LNA, locked nucleic acids; NC, negative control; LDLR, LDL receptor. The significance is indicated only for samples that are significantly different from all the others. * P<.05; ** P<0.01; *** P<0.001.
Sandwich Elisa Kit Detection Ldlr, supplied by Cell Biolabs Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/ldlr+elisa+kit/sandwich+elisa+kit+detection+ldlr/pmc04575910-137-13-14
Average 90 stars, based on 1 article reviews
sandwich elisa kit detection ldlr - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

N/A
This ELISA kit uses the Sandwich-ELISA principle. The micro ELISA plate provided in this kit has been pre-coated with an antibody specific to Mouse LDLR. Standards or samples are added to the micro ELISA plate
  Buy from Supplier


N/A
For quantitative detection of mouse LDLR in cell culture supernates serum plasma heparin and urine
  Buy from Supplier

N/A
An ELISA kit for the detection of Ldlr Mouse This uses Sandwich ELISA Double Antibody and has a sensitivity of 0 094ng ml
  Buy from Supplier

N/A
For the quantitative determination of Human LDL Receptor / LDLR concentration in serum.
  Buy from Supplier

Image Search Results


The pharmacophore model of the LDLR-binding domain in PCSK9 was established using MOE. Pharmacophore features include: F1, an aromatic feature; F2 and F4, hydrogen-bond acceptor features; F3, a hydrogen-bond donor feature.

Journal: Journal of Enzyme Inhibition and Medicinal Chemistry

Article Title: Identification of a peptide inhibitor disrupting the PCSK9-LDLR interaction via pharmacophore-based virtual screening, molecular dynamics simulations and in vitro/vivo evaluation

doi: 10.1080/14756366.2025.2610849

Figure Lengend Snippet: The pharmacophore model of the LDLR-binding domain in PCSK9 was established using MOE. Pharmacophore features include: F1, an aromatic feature; F2 and F4, hydrogen-bond acceptor features; F3, a hydrogen-bond donor feature.

Article Snippet: The supernatants were used to determine hepatic LDLR protein levels using a mouse LDLR ELISA kit (R&D Systems).

Techniques: Binding Assay

The 2D interaction plots for TPPs 1–5 and the LDLR-binding domain in PCSK9 using the LigPlot. The hydrogen bonds are shown in green.

Journal: Journal of Enzyme Inhibition and Medicinal Chemistry

Article Title: Identification of a peptide inhibitor disrupting the PCSK9-LDLR interaction via pharmacophore-based virtual screening, molecular dynamics simulations and in vitro/vivo evaluation

doi: 10.1080/14756366.2025.2610849

Figure Lengend Snippet: The 2D interaction plots for TPPs 1–5 and the LDLR-binding domain in PCSK9 using the LigPlot. The hydrogen bonds are shown in green.

Article Snippet: The supernatants were used to determine hepatic LDLR protein levels using a mouse LDLR ELISA kit (R&D Systems).

Techniques: Binding Assay

The 3D interaction plots for TPPs 1–5 and the LDLR-binding domain in PCSK9. (A, B) TPP-1 are colour-coded by yellow. (C, D) TPP-2, purple; (E, F) TPP-3, orange; (G, H) TPP-4, cyan; (I, J) TPP-5, green. The LDLR-binding domain residues of PCSK9 are displayed as sticks: nitrogen atoms are blue, oxygen atoms are red, and other residues are silver.

Journal: Journal of Enzyme Inhibition and Medicinal Chemistry

Article Title: Identification of a peptide inhibitor disrupting the PCSK9-LDLR interaction via pharmacophore-based virtual screening, molecular dynamics simulations and in vitro/vivo evaluation

doi: 10.1080/14756366.2025.2610849

Figure Lengend Snippet: The 3D interaction plots for TPPs 1–5 and the LDLR-binding domain in PCSK9. (A, B) TPP-1 are colour-coded by yellow. (C, D) TPP-2, purple; (E, F) TPP-3, orange; (G, H) TPP-4, cyan; (I, J) TPP-5, green. The LDLR-binding domain residues of PCSK9 are displayed as sticks: nitrogen atoms are blue, oxygen atoms are red, and other residues are silver.

Article Snippet: The supernatants were used to determine hepatic LDLR protein levels using a mouse LDLR ELISA kit (R&D Systems).

Techniques: Binding Assay

The surface LDLR expression in HepG2 cells. (A) HepG2 cells treated with TPPs 1–5, Pep2-8, and Evolocumab. (B) HepG2 cells treated with TPP-4 at different concentrations. *** P < 0.001 vs Pep2-8.

Journal: Journal of Enzyme Inhibition and Medicinal Chemistry

Article Title: Identification of a peptide inhibitor disrupting the PCSK9-LDLR interaction via pharmacophore-based virtual screening, molecular dynamics simulations and in vitro/vivo evaluation

doi: 10.1080/14756366.2025.2610849

Figure Lengend Snippet: The surface LDLR expression in HepG2 cells. (A) HepG2 cells treated with TPPs 1–5, Pep2-8, and Evolocumab. (B) HepG2 cells treated with TPP-4 at different concentrations. *** P < 0.001 vs Pep2-8.

Article Snippet: The supernatants were used to determine hepatic LDLR protein levels using a mouse LDLR ELISA kit (R&D Systems).

Techniques: Expressing

(A) Liver LDLR levels in mice treated with TPP-4 and Evolocumab. (B) Plasma total cholesterol levels in mice treated with TPP-4 and Evolocumab.

Journal: Journal of Enzyme Inhibition and Medicinal Chemistry

Article Title: Identification of a peptide inhibitor disrupting the PCSK9-LDLR interaction via pharmacophore-based virtual screening, molecular dynamics simulations and in vitro/vivo evaluation

doi: 10.1080/14756366.2025.2610849

Figure Lengend Snippet: (A) Liver LDLR levels in mice treated with TPP-4 and Evolocumab. (B) Plasma total cholesterol levels in mice treated with TPP-4 and Evolocumab.

Article Snippet: The supernatants were used to determine hepatic LDLR protein levels using a mouse LDLR ELISA kit (R&D Systems).

Techniques: Clinical Proteomics

Translation of LDLR protein is enhanced by targeting the predicted structure using an ASO. ( A ) The potential effect of an ASO on the predicted structure is depicted. ( B ) ELISA analyses for LDLR protein levels in HEK293 cells transfected for 15 h with XL824, which targets the 5′ side of the predicted stem. ( C ) qRT-PCR quantification of LDLR mRNA in cells treated with XL824. ( D ) ELISA analyses for LDLR protein in HEK293 cells transfected for 15 h with ASO814923, targeting the 3′ side of the potential stem or an ASO XL506 targeting a potential uORF. ASO concentration 0 indicates mock transfection. ( E ) Western analyses for LDLR protein in HEK293 cells treated with 30 nM ASO814923 for 10 h. Levels were normalized to those of GAPDH. ( F ) qRT-PCR quantification of LDLR mRNA levels in HEK293 cells treated with the ASO. ( G ) Autoradiography of 35 S-methionine-labeled nascent LDLR protein isolated by immunoprecipitation from cells treated with ASO814923 (+) or mock-treated (–) for 7 h. An aliquot of cell lysate used for immunoprecipitation was analyzed by SDS-PAGE, and labeled nascent proteins were visualized by autoradiography (right panel). The level of nascent LDLR protein was normalized to signal from band marked by an arrow, and relative levels are given below the lanes. ( H ) qRT-PCR quantification of LDLR mRNA co-immunoprecipitated using an anti-eIF4A antibody or control IgG from mock transfected HEK293 cells (UTC) or cells treated with the ASO814923 for 10 h. 7SL RNA and RNASEH1 mRNA were quantified as controls. ( I ) LDL uptake in HEK293 cells treated with 30 nM ASO814923 or 30 nM control ASO812662 for 15 h. ( J ) qRT-PCR for LDLR mRNA levels in HEK293 cells treated with siRNA targeting luc or LDLR for 4 h, followed by treatment with or without ASO814923 (40 nM) for an additional 10 h. ( K ) ELISA analyses for LDLR protein levels in HEK293 cells treated with siRNAs, followed by treatment with ASO814923. ( L ) LDL uptake in HEK293 cells treated with siRNAs for 4 h, followed by treatment of the ASO for 10 h, and LDL uptake analysis. The error bars are standard deviations from three experiments. P -values were calculated based on unpaired t-test. NS, not significant. ** P < 0.01; *** P < 0.001 and **** P < 0.0001.

Journal: Nucleic Acids Research

Article Title: Antisense oligonucleotides targeting translation inhibitory elements in 5′ UTRs can selectively increase protein levels

doi: 10.1093/nar/gkx632

Figure Lengend Snippet: Translation of LDLR protein is enhanced by targeting the predicted structure using an ASO. ( A ) The potential effect of an ASO on the predicted structure is depicted. ( B ) ELISA analyses for LDLR protein levels in HEK293 cells transfected for 15 h with XL824, which targets the 5′ side of the predicted stem. ( C ) qRT-PCR quantification of LDLR mRNA in cells treated with XL824. ( D ) ELISA analyses for LDLR protein in HEK293 cells transfected for 15 h with ASO814923, targeting the 3′ side of the potential stem or an ASO XL506 targeting a potential uORF. ASO concentration 0 indicates mock transfection. ( E ) Western analyses for LDLR protein in HEK293 cells treated with 30 nM ASO814923 for 10 h. Levels were normalized to those of GAPDH. ( F ) qRT-PCR quantification of LDLR mRNA levels in HEK293 cells treated with the ASO. ( G ) Autoradiography of 35 S-methionine-labeled nascent LDLR protein isolated by immunoprecipitation from cells treated with ASO814923 (+) or mock-treated (–) for 7 h. An aliquot of cell lysate used for immunoprecipitation was analyzed by SDS-PAGE, and labeled nascent proteins were visualized by autoradiography (right panel). The level of nascent LDLR protein was normalized to signal from band marked by an arrow, and relative levels are given below the lanes. ( H ) qRT-PCR quantification of LDLR mRNA co-immunoprecipitated using an anti-eIF4A antibody or control IgG from mock transfected HEK293 cells (UTC) or cells treated with the ASO814923 for 10 h. 7SL RNA and RNASEH1 mRNA were quantified as controls. ( I ) LDL uptake in HEK293 cells treated with 30 nM ASO814923 or 30 nM control ASO812662 for 15 h. ( J ) qRT-PCR for LDLR mRNA levels in HEK293 cells treated with siRNA targeting luc or LDLR for 4 h, followed by treatment with or without ASO814923 (40 nM) for an additional 10 h. ( K ) ELISA analyses for LDLR protein levels in HEK293 cells treated with siRNAs, followed by treatment with ASO814923. ( L ) LDL uptake in HEK293 cells treated with siRNAs for 4 h, followed by treatment of the ASO for 10 h, and LDL uptake analysis. The error bars are standard deviations from three experiments. P -values were calculated based on unpaired t-test. NS, not significant. ** P < 0.01; *** P < 0.001 and **** P < 0.0001.

Article Snippet: Around 10 μg total protein was analyzed using an ELISA kit (DLDLR0, R&D Systems) for human LDLR based on the manufacturer's protocol.

Techniques: Enzyme-linked Immunosorbent Assay, Transfection, Quantitative RT-PCR, Concentration Assay, Western Blot, Autoradiography, Labeling, Isolation, Immunoprecipitation, SDS Page, Control

ASOs with different modifications can increase LDLR protein levels. ( A ) ELISA analysis for LDLR protein levels in HeLa cells treated with ASO842196 for 15 h at different concentrations. ( B ) ELISA analyses for LDLR protein levels in HEK293 cells transfected with ASO842196, ASO842197, or ASO842206 at indicated concentrations for 12 h. Means ± standard deviations of three independent experiments are plotted. P -values were calculated based on unpaired t -test. *** P < 0.001; **** P < 0.0001.

Journal: Nucleic Acids Research

Article Title: Antisense oligonucleotides targeting translation inhibitory elements in 5′ UTRs can selectively increase protein levels

doi: 10.1093/nar/gkx632

Figure Lengend Snippet: ASOs with different modifications can increase LDLR protein levels. ( A ) ELISA analysis for LDLR protein levels in HeLa cells treated with ASO842196 for 15 h at different concentrations. ( B ) ELISA analyses for LDLR protein levels in HEK293 cells transfected with ASO842196, ASO842197, or ASO842206 at indicated concentrations for 12 h. Means ± standard deviations of three independent experiments are plotted. P -values were calculated based on unpaired t -test. *** P < 0.001; **** P < 0.0001.

Article Snippet: Around 10 μg total protein was analyzed using an ELISA kit (DLDLR0, R&D Systems) for human LDLR based on the manufacturer's protocol.

Techniques: Enzyme-linked Immunosorbent Assay, Transfection

PCSK9 vaccine (V2 vaccine) or control (Saline) was injected at different doses (Low; 5 μg and High; 50 μg peptides per mouse) three times in biweekly intervals (0, 2, and 4 weeks). (A) Anti-PCSK9 antibody titers (OD50%) were evaluated at pre-immunization (pre) and post-immunization time points (2, 4, 6, 8, 12, 16, 20, and 24 weeks). Data are presented as the average of each groups; error bars indicate the SEM. **P<0.01 and ****P<0.0001 show significant changes between low dose group and saline group. ††††P<0.0001 shows significant changes between high dose group and saline group. (B) PCSK9 levels in plasma samples from pre-immunized (pre) and post-immunized (6 weeks) mice. Bars represent mean levels of detected mouse PCSK9 levels in plasma samples, and error bars represent ± SEM. Significance values relative to saline group (*P<0.05, ***P<0.001) were obtained using two-way ANOVA with subsequent Tukey's multiple comparisons tests. (C) Cell-surface LDLR levels in liver hepatocytes were measured in immunized mice at 6 weeks post-immunization via ELISA. The results are presented as a fold-increase relative to saline-treated groups. Significance values relative to saline (****P<0.0001) were obtained with one-way ANOVA with subsequent Tukey’s tests for multiple comparisons. All data in this Figure are expressed as the means ± SEM.

Journal: PLoS ONE

Article Title: Development of vaccine for dyslipidemia targeted to a proprotein convertase subtilisin/kexin type 9 (PCSK9) epitope in mice

doi: 10.1371/journal.pone.0191895

Figure Lengend Snippet: PCSK9 vaccine (V2 vaccine) or control (Saline) was injected at different doses (Low; 5 μg and High; 50 μg peptides per mouse) three times in biweekly intervals (0, 2, and 4 weeks). (A) Anti-PCSK9 antibody titers (OD50%) were evaluated at pre-immunization (pre) and post-immunization time points (2, 4, 6, 8, 12, 16, 20, and 24 weeks). Data are presented as the average of each groups; error bars indicate the SEM. **P<0.01 and ****P<0.0001 show significant changes between low dose group and saline group. ††††P<0.0001 shows significant changes between high dose group and saline group. (B) PCSK9 levels in plasma samples from pre-immunized (pre) and post-immunized (6 weeks) mice. Bars represent mean levels of detected mouse PCSK9 levels in plasma samples, and error bars represent ± SEM. Significance values relative to saline group (*P<0.05, ***P<0.001) were obtained using two-way ANOVA with subsequent Tukey's multiple comparisons tests. (C) Cell-surface LDLR levels in liver hepatocytes were measured in immunized mice at 6 weeks post-immunization via ELISA. The results are presented as a fold-increase relative to saline-treated groups. Significance values relative to saline (****P<0.0001) were obtained with one-way ANOVA with subsequent Tukey’s tests for multiple comparisons. All data in this Figure are expressed as the means ± SEM.

Article Snippet: LDLR concentration were calculated using a Mouse LDLR Immunoassay in the Quantikine ® ELISA kit (R&D SYSTEMS, Inc., Minneapolis, MN, USA, MLDLR0), according to the manufacturer’s instructions.

Techniques: Control, Saline, Injection, Clinical Proteomics, Enzyme-linked Immunosorbent Assay

(A) Predicted annealing of human miR-27a to two sites on the LDLR 3′UTR. HepG2 cells were transfected with different concentrations of either LNA anti-miR-27a or LNA NC. (B) Cells were transfected with either 30 nM miR-27a, 30 nM NC mimic, 50 nM LNA anti-miR-27a or 50 nM LNA NC. The level of LDLR mRNA was quantified by TaqMan qPCR and the LDLR protein by ELISA. (C and D) Cells were co-transfected with 1 μg of reporter constructs pLDLR-3′UTR, pmiR-27a or mutated pmiR-27aM in the presence or absence of either 50 nM LNA anti-miR-27a, 50 nM LNA NC, 30 nM miR-27a or 30 nM NC mimic. (E) LDLR activity was assessed in HepG2 cells transfected with either 30 nM miR-27a or NC mimics and incubated overnight with LDL conjugated to DyLight™ 549, a fluorescent probe for detection of LDL uptake. The degree of LDL uptake was examined in an Evos Digital Inverted Fluorescence Microscope (AMG, Fisher Scientific) with filters for excitation at 540 nm and emission at 570 nm. (F) The intensity of fluorescence was quantified at 540/570 nm excitation/emission using a Synergy MX plate reader (Biotek). Data are mean of three independent experiments ± S.D. LNA, locked nucleic acids; NC, negative control; LDLR, LDL receptor. The significance is indicated only for samples that are significantly different from all the others. * P<.05; ** P<0.01; *** P<0.001.

Journal: Atherosclerosis

Article Title: MicroRNA-27a decreases the level and efficiency of the LDL receptor and contributes to the dysregulation of cholesterol homeostasis

doi: 10.1016/j.atherosclerosis.2015.08.023

Figure Lengend Snippet: (A) Predicted annealing of human miR-27a to two sites on the LDLR 3′UTR. HepG2 cells were transfected with different concentrations of either LNA anti-miR-27a or LNA NC. (B) Cells were transfected with either 30 nM miR-27a, 30 nM NC mimic, 50 nM LNA anti-miR-27a or 50 nM LNA NC. The level of LDLR mRNA was quantified by TaqMan qPCR and the LDLR protein by ELISA. (C and D) Cells were co-transfected with 1 μg of reporter constructs pLDLR-3′UTR, pmiR-27a or mutated pmiR-27aM in the presence or absence of either 50 nM LNA anti-miR-27a, 50 nM LNA NC, 30 nM miR-27a or 30 nM NC mimic. (E) LDLR activity was assessed in HepG2 cells transfected with either 30 nM miR-27a or NC mimics and incubated overnight with LDL conjugated to DyLight™ 549, a fluorescent probe for detection of LDL uptake. The degree of LDL uptake was examined in an Evos Digital Inverted Fluorescence Microscope (AMG, Fisher Scientific) with filters for excitation at 540 nm and emission at 570 nm. (F) The intensity of fluorescence was quantified at 540/570 nm excitation/emission using a Synergy MX plate reader (Biotek). Data are mean of three independent experiments ± S.D. LNA, locked nucleic acids; NC, negative control; LDLR, LDL receptor. The significance is indicated only for samples that are significantly different from all the others. * P<.05; ** P<0.01; *** P<0.001.

Article Snippet: Protein concentration was determined using a commercial sandwich ELISA kit for detection of LDLR (Cell Biolabs; San Diego, CA) and PCSK9 (R&D Systems; Minneapolis, MN) according to the manufacturer’s instructions.

Techniques: Transfection, Enzyme-linked Immunosorbent Assay, Construct, Activity Assay, Incubation, Fluorescence, Microscopy, Negative Control